Translational cancer research
Cure8 research brief
Why This Matters
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify higher-risk patients or new therapeutic strategies.
Who Should Pay Attention
Researchers, translational scientists, gastroenterology clinicians, and patients interested in UC–colorectal cancer risk research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used multi-omics and single-cell RNA sequencing analyses to identify PPARGC1A as a gene that is downregulated in intestinal epithelial cells in ulcerative colitis and colorectal cancer.
The authors report that low PPARGC1A expression is present early in the progression from UC to UC-associated CRC and is associated with features linked to more aggressive disease (for example, EMT and altered mTORC1 signaling) and an immunosuppressive tumor microenvironment.
They also performed in silico drug-sensitivity prediction and molecular docking to suggest possible avenues for therapeutic development.
PPARGC1A is presented here as a potential early biomarker for patients with UC who may be at higher risk for progression to colorectal cancer, and as a candidate therapeutic target; however, the findings are based on computational integration of public datasets and laboratory-style analyses rather than prospective clinical testing.
If you are a patient or caregiver, this does not change clinical care now but points to a possible future biomarker or drug-development target that will need further validation in clinical studies before it could affect screening or treatment decisions.
Keep In Mind
Findings are based on integrated database analyses, single-cell transcriptomics, and computational drug-sensitivity/docking predictions; clinical validation is not provided in this report.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTranslational cancer research
AuthorsFan B, Li W, Wei Z
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedMay 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Multi-omics Mendelian randomization and experimental validation identify PRKAB1 as a regulator of phosphatidylcholine metabolism in IBD.
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Multi-Omics Framework Integrating Genetics, Microbiome, Metabolism, and Immunity for Deciphering Ulcerative Colitis Pathogenesis and Diagnostic Biomarker Discovery.
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
Risk of Inflammatory Bowel Disease Following Hospital-Treated Infections and Modulatory Role of Host Genetics to Support a Multi-Hit Pathogenesis Model.
If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...